SCHEMBL5041679

SCHEMBL5041679

N#Cc1c(NCCOc2ccccc2)nc(N)nc1-c1ccco1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 10/20 0.57
ADORA1 P30542 10/20 0.57
ADORA2B P29275 8/20 0.57
ALDH1A1 P00352 7/20 0.48
KDM4E B2RXH2 6/20 0.48
HPGD P15428 6/20 0.48
LMNA P02545 2/20 0.48
POLB P06746 2/20 0.48
SMARCA2 P51531 1/20 0.48
GAA P10253 4/20 0.44
GLA P06280 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
AURKA O14965 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 1/20 0.43
STAT6 P42226 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441748 0.86 ADORA1 (0.54) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL5036673 0.85 ADORA2A (0.61) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6446426 0.84 ADORA2A (0.60) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL5039880 0.83 ADORA2A (0.57) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6441991 0.82 ADORA2A (0.57) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL5039809 0.82 ADORA2A (0.58) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL5040171 0.81 ADORA2A (0.62) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6441717 0.81 ADORA2A (0.57) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6446625 0.81 ADORA2A (0.57) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL5046655 0.81 ADORA2A (0.54) ADORA2AADORA1ADORA2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4064671-B2 2008-03-19 JP claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP claimed
JP-2003523380-A 2003-08-05 JP claimed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US claimed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP claimed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US claimed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.